International: +1-347-960-6455
Infertility Therapeutics - Pipeline Analysis 2018

Infertility Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments

Report Code: PP10142 Report Type: Indication Pipeline Reports Available format: 
Therapeutic Area(s): Others
Select License Type

Infertility is defined as the biological inability to conceive or contribute to conception, after having regular unprotected sex. According to the data published by the Department of Health and Human Services, approximately 10% to 15% of couples in the U.S. are infertile and have not conceived after at least one year of regular, unprotected sex. Infertility may have a single cause in one of the partners, or it could be the result of a combination of factors. Some of the causes of infertility are ovulation disorders in women, chemotherapy, radiotherapy, use of illegal drugs, and testicular infections in men.  Risk factors associated with infertility are smoking, alcohol consumption, obesity, eating disorders, over-exercising, inactivity, sexually transmitted infections (STIs), mental stress, and exposure to some chemicals. Ferring International Center S.A. is in the process of developing FE 999310, for the treatment of infertility. Some of the companies having a pipeline of infertility include CellOxess LLC, TocopheRx, and others.

  • The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.
  • Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.